沙库巴曲缬沙坦钠联合阿托伐他汀治疗急性ST段抬高型心肌梗死合并心力衰竭的临床疗效<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2026.04.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1198 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of sacubitril valsartan sodium combined with atorvastatin in patients with acute ST-segment elevation myocardial infarction (STEMI) complicated with heart failure (HF). 【Methods】 A total of 80 patients with STEMI complicated with HF admitted to our hospital from June 2022 to October 2024 were enrolled and randomly divided into a control group and an observation group using a random number table, with 40 cases in each group. The control group received atorvastatin calcium tablets on the basis of conventional treatment, while the observation group was additionally given sacubitril valsartan sodium tablets on the basis of the control group. Clinical efficacy, cardiac function indexes [left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD)], oxidative stress indexes [superoxide dismutase (SOD), malondialdehyde (MDA)], myocardial injury markers [N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI)], vascular endothelial function indexes [vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), nitric oxide (NO)], myocardial energy metabolism indexes [free fatty acid (FFA), circumferential end-systolic wall stress (cESS), myocardial energy expenditure (MEE)], and the incidence of adverse reactions were compared between the two groups. 【Results】 The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, LVEF in both groups was increased, while LVESD and LVEDD were decreased compared with baseline; the observation group had higher LVEF and lower LVESD and LVEDD than the control group (all P<0.05). MDA was decreased and SOD was increased in both groups, with lower MDA and higher SOD in the observation group (P<0.05). Levels of NT-proBNP, CK-MB and cTnI were all reduced in both groups, and were lower in the observation group (P<0.05). Levels of NO and VEGF were elevated while ET-1 was reduced in both groups, with higher NO and VEGF and lower ET-1 in the observation group (P<0.05). FFA, cESS and MEE were decreased in both groups, and were lower in the observation group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). 【Conclusion】 Sacubitril valsartan sodium combined with atorvastatin shows favorable clinical efficacy in STEMI patients complicated with HF. It can regulate oxidative stress and myocardial energy metabolism, protect cardiomyocytes and vascular endothelial function, and presents good safety.

Key words： ST Elevation Myocardial Infarction Acute Disease Heart Failure Valsartan Atorvastatin Drug Therapy, Combination

Received: 20 October 2025

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Guanying
	ZHANG Lihua
	SHAN Qiuju
	XIONG Haiyan
	LI Yan
	WANG Zhenzhen
	LIU Yikai
	SUN Liqiang

Cite this article:

JIANG Guanying,ZHANG Lihua,SHAN Qiuju, et al. Clinical Efficacy of Sacubitril Valsartan Sodium Combined with Atorvastatin in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Complicated with Heart Failure[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(4): 532-536.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.04.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I4/532

[1] 周智华,袁晓霞,周尚成. 2015—2019年广州市急性心肌梗死死亡特征及疾病负担分析[J].现代预防医学,2022,49(4):577-580.
[2] 周鹏飞,曹繁,尹成龙. CHE、sST2对心肌梗死合并心力衰竭患者短期死亡的预测价值[J].心血管康复医学杂志,2025,34(4):492-497.
[3] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. ST段抬高型心肌梗死基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(12):1083-1091.
[4] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[5] HONG S J, LEE Y J, KANG W C, et al. Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial[J].Cardiovasc Diabetol,2024,23(1):287.
[6] ZHU T Y, SONG Y J. Efficacy of Sacubitril/Valsartan combined with metoprolol on cardiac function, cardiac remodeling, and endothelial function in patients with coronary heart disease and heart failure[J].Br J Hosp Med (Lond),2025,86(4):1-16.
[7] 苏文刚,杨海洋,孙富强. 老年慢性心力衰竭患者心肌能量代谢改变及其与不良心血管事件的关联[J].中华老年心脑血管病杂志,2024,26(11):1296-1300.
[8] 曹位平,王盛尧,罗永全,等. STEMI患者PCI治疗前外周血miR-1、miR-21表达水平与细胞因子、氧化应激及治疗后冠状动脉再狭窄的关系[J].岭南心血管病杂志,2021,27(2):127-131.
[9] 王健兵,阴丽,万艳,等. 探讨再灌注时间与心律失常发生率关系以及氧化应激、炎症反应变化趋势[J].兰州大学学报(医学版),2021,47(6):68-73.
[10] LEI X T, PU D L, SHAN G, et al. Atorvastatin ameliorated myocardial fibrosis by inhibiting oxidative stress and modulating macrophage polarization in diabetic cardiomyopathy[J].World J Diabetes,2024,15(6):1070-1073.
[11] 王颖,邵旭武,王学忠,等. 沙库巴曲缬沙坦钠对慢性心力衰竭患者氧化应激及心肌能量代谢的影响[J].联勤军事医学,2023,37(3):222-226.
[12] 梁肖倩,张继伟,刘红涛. 参桂胶囊联合沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果及对血清血管紧张素Ⅱ和B型脑钠肽水平的影响[J].中国医药,2025,20(8):1218-1222.
[13] 唐惠星,刘倩,李群,等. 血清NT-proBNP、cTnI及CK-MB与急性心梗患者近期预后的关系[J].分子诊断与治疗杂志,2022,14(5):756-759.
[14] 赵沱,任园园,程涛. 高压氧联合阿托伐他汀治疗对冠心病PCI术后血管内皮功能、凝血功能及炎症反应的影响[J].中华航海医学与高气压医学杂志,2025,32(3):271-276.
[15] 赖增华,窦学凯,陈瑞娟,等. 急性心肌梗死患者冠状动脉病变程度与血清血管内皮生长因子、脂蛋白(a)、总胆红素的相关性[J].心脑血管病防治,2023,23(10):25-29.
[16] 赵鑫龙,杨杰孚. 心肌能量代谢与心力衰竭的研究进展[J].中华心血管病杂志,2022,50(4):404-409.